Dr. Eugene Brandon leads the business development and operations at the IQVIA CAGT Translating Center, and is a strategy lead and subject matter expert for cell & gene therapeutics, with a focus on CMC and pre-clinical elements. Dr. Brandon has over 25 years’ experience in regenerative medicine innovation in both industry and academics (NEMC, Salk Institute, Ceregene, ViaCyte) with particular expertise in neuroscience and neurodegeneration, immunology, endocrinology, and oncology. He has managed numerous interdisciplinary and collaborative multi-institutional teams on complex projects, and represented key industry opinion on CMC and non-clinical matters related to pluripotent stem cell-based medicine including to FDA, NIH, CIRM, and ARM. He has led product development, process development, non-clinical work, and regulatory submissions for several leading-edge product candidates. Dr. Brandon also volunteers as a Trustee and chairs the Research Committee of the ALS Association. He has a PhD in Pharmacology and a certificate in Biotechnology Project Management.